Bullet Point Summary
What is already known
PP242 is an ATP-competitive mTOR inhibitor that represents promising
anticancer activity against various cancers.
What this study adds
- The antitumor activity of PP242 is mainly associated with energy and
glycerophospholipid metabolism.
- Both the TCA cycle and fatty acid β-oxidation (β-FAO) for energy
metabolism were inhibited.
Clinical significance
This study can help to further understand the therapeutic effects of
PP242 in clinical applications.